Patent ID: 6147092
Filing Date: 2000-11-14
Classification: A61P,C07D

Abstract:
A method for inhibiting estrogen-dependent cancer comprising administering to a human in need thereof a compound of formula (I): ##STR3## wherein: R.sub.1 is N-pyrrolidinyl or N-piperidinyl;R.sub.2 and R.sub.3 are independently hydrogen, --CO--(C.sub.10 -C.sub.22 alkyl), --CO--(C.sub.10 -C.sub.22 branched alkyl), --CO--(C.sub.10 -C.sub.22 alkenyl), --CO--(C.sub.10 -C.sub.22 polyalkenyl), --CO--(C.sub.10 -C.sub.22 alkynyl), or --CO--(CH.sub.2).sub.n COR.sub.4 ; provided that when R.sub.1 is N-piperidinyl, neither R.sub.2 or R.sub.3 is --CO--(C.sub.10 -C.sub.22 alkyl) or --CO--(C.sub.10 -C.sub.22 branched alkyl); and provided one of R.sub.2 or R.sub.3 is not hydrogen;R.sub.4 is -3-cholesteryl or --O(CH.sub.2).sub.2 (OR.sub.5)CH.sub.2 OR.sub.6 ;R.sub.5 and R.sub.6 are independently hydrogen, --CO--(C.sub.10 -C.sub.22 alkyl), --CO--(C.sub.10 -C.sub.22 branched alkyl), --CO--(C.sub.10 -C.sub.22 alkenyl), --CO--(C.sub.10 -C.sub.22 polyalkenyl), or --CO--(C.sub.10 -C.sub.22 alkynyl); provided one of R.sub.5 or R.sub.6 is not hydrogen; andn is 0-4; or a pharmaceutically acceptable salt or solvate thereof.